Synthetic lethality and the treatment of cancer
Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.
1. A method of treating a human subject having Burkitt's lymphoma that expresses an N-myristoyltransferase 1 (NMT1) protein and comprises a loss of N-myristoyltransferase 2 (NMT2) protein activity or level as compared to normal human B cells, comprising:
administering to said human subject a therapeutically effective amount of an inhibitor of NMT1 protein, wherein said NMT1 inhibitor inhibits NMT1 protein activity, wherein said NMT1 inhibitor is DDD85646, or a derivative thereof.
2. The method of claim 1 , further comprising administering a chemotherapeutic agent to said human subject.
3. The method of claim 2 , wherein said chemotherapeutic agent is CHOP, GAP-BOP, m-BACOD, ProMACE-MOPP, ProMACE-CytaBOM, MACOP-B, IMVP- 16, MIME, DHAP, ESHAP, CEFF(B), CAMP, VABCD, ABDIC, CBVD, PCVP, CEP, EVA, MOPLACE, MIME, MINE, MTX-CHOP, CEM, CEVD, CAVP, EVAP, or EPOCH.
4. A treatment method comprising administering DDD85646 or a derivative thereof to a human subject identified as having Burkitt's lymphoma that expresses an N-myristoyltransferase 1 (NMT1) protein and comprises a loss of N-myristoyltransferase 2 (NMT2) protein activity or level as compared to normal human B cells.
5. The method of claim 4 , further comprising administering a chemotherapeutic agent to said human subject.
6. The method of claim 5 , wherein said chemotherapeutic agent is CHOP, GAP-BOP, m-BACOD, ProMACE-MOPP, ProMACE-CytaBOM, MACOP-B, IMVP- 16, MIME, DHAP, ESHAP, CEFF(B), CAMP, VABCD, ABDIC, CBVD, PCVP, CEP, EVA, MOPLACE, MIME, MINE, MTX-CHOP, CEM, CEVD, CAVP, EVAP, or EPOCH.